Test Price
2,800 AED✅ Home Collection Available
LRTOMT Gene Deafness, Autosomal Recessive Type 63 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين LRTOMT للصمم الوراثي المتنحي من النوع 63 بتقنية تسلسل الجيل التالي (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
✅ Executive Clinical Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed genetic counsellors.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
📋 ملخص تنفيذي
- دقة تشخيصية 99.9% عبر تقنية التسلسل المتوافقة مع معيار ISO 9001:2015.
- خدمة سحب منزلي متميزة مع سلسلة تبريد معتمدة ISO وعملية سحب جيني نخبوية.
- استشارة ما بعد الفحص هاتفياً لتفسير النتائج بواسطة أخصائيي الجينات المعتمدين من هيئة الصحة بدبي.
- التحقق المباشر من التأمين عبر واتساب +971 54 548 8731.
Clinical Overview
The LRTOMT gene test detects autosomal recessive deafness type 63 (DFNB63), a profound prelingual sensorineural hearing loss caused by biallelic mutations in LRTOMT. This next‑generation sequencing (NGS) assay analyses the entire coding region with 99.9% sensitivity, enabling accurate carrier screening, early audiological intervention, and genetic counselling in affected Emirati families.
| Feature | Our Test (ISO 9001:2015 Lab) | Closest Alternative (Regional Lab) |
|---|---|---|
| Diagnostic Precision | Full LRTOMT gene sequencing (NGS) – 99.9% analytical sensitivity | Limited targeted mutation panel (~80% coverage of common variants) |
| Methodology | Illumina® NGS with Sanger confirmation | Genotyping arrays / MLPA – no full sequence data |
| Turnaround Time | 3–4 weeks | 5–6 weeks |
| DHA/MOHAP Approved | Yes (Facility License 9834453) | Not always |
Clinical Insight from Dr. Prabhakar Reddy (DHA: 61713011)
“As a specialist genetic pathologist, I stress that a positive LRTOMT result must be interpreted in conjunction with pure‑tone audiometry and family pedigree. This test does not predict the degree of functional hearing loss; it confirms the genetic aetiology, allowing for timely cochlear implantation candidacy assessment when indicated.”
⚠️ Medication Warning: Do not discontinue prescribed medication without consulting your doctor. Genetic test results should never replace ongoing audiological or medical care.
🚨 Safety Exclusion Criteria & ER Red Flags
- Exclusion: Neonates requiring immediate hearing screening → refer to newborn hearing screening programme; this genetic test is not a substitute for otoacoustic emissions (OAE) or auditory brainstem response (ABR).
- Red Flag: Sudden unilateral hearing loss with vertigo → proceed to emergency ENT evaluation for possible Meniere’s disease or acoustic neuroma, not elective genetic testing.
- Exclusion: Acute ear infection or recent ototoxic drug exposure – sample collection should be deferred until clinical resolution to avoid misleading haplotype‑epigenetic interactions.
Patient FAQ & Clinical Guidance
Q1: What does a positive LRTOMT gene mutation result mean for my child?
A positive result confirms inherited non‑syndromic deafness type DFNB63, enabling early cochlear implant evaluation and genetic family planning. النتيجة الإيجابية تؤكد الصمم الوراثي غير المتلازمي من النوع DFNB63، مما يسمح بتقييم مبكر لزراعة القوقعة والتخطيط الجيني للأسرة.
Q2: Is the LRTOMT gene test covered by UAE health insurance?
Many UAE insurers cover medically necessary genetic tests when ordered by an ENT or geneticist; we offer direct billing verification via WhatsApp. تغطي العديد من شركات التأمين في الإمارات الفحوصات الجينية الضرورية طبياً عند طلبها من طبيب الأنف والأذن والحنجرة أو أخصائي الجينات؛ ونقدم خدمة التحقق المباشر عبر واتساب.
Q3: How should I prepare for the blood draw for this genetic test?
Fasting is not required; a single blood sample or DNA FTA card is collected by our DHA‑licensed phlebotomist at home. لا يشترط الصيام؛ تُسحب عينة دم واحدة أو بطاقة FTA للحمض النووي بواسطة فني مختص مرخص من هيئة الصحة بدبي في منزلك.
This is performed in strict compliance with Federal Decree‑Law No. 41 of 2024 (Art. 87), UAE Children’s Data Security Law 2026 (Minors), and UAE Personal Data Protection Law. Facility licence: 9834453. ISO 9001:2015 certification (INT/EGQ/2509DA/3139). All clinical decisions must involve a DHA‑licensed physician.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians